Takeshi Iwatsubo, MD, PhD

Articles by Takeshi Iwatsubo, MD, PhD

Early Clinical Use of Anti-Amyloid Therapy for Alzheimer Disease in Japan: Takeshi Iwatsubo, MD, PhD

November 8th 2024

The professor of neuropathology at the University of Tokyo School of Medicine talked about the latest data on lecanemab use in clinical practice for Alzheimer disease in Japan presented at CTAD 2024. [WATCH TIME: 4 minutes]

Latest Updated Articles

FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease
Published: August 29th 2025 | Updated: September 2nd 2025
Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over Donanemab
Published: July 28th 2025 | Updated: July 30th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on Term
Published: May 14th 2025 | Updated: May 16th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack Severity
Published: May 12th 2025 | Updated: May 13th 2025
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
Published: March 4th 2025 | Updated: March 19th 2025

Takeshi Iwatsubo, MD, PhD

Articles by Takeshi Iwatsubo, MD, PhD

Early Clinical Use of Anti-Amyloid Therapy for Alzheimer Disease in Japan: Takeshi Iwatsubo, MD, PhD

Latest Updated Articles

Trending on NeurologyLive

Expanding the Alzheimer Drug Development Pipeline

MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne

DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point

NeurologyLive® Friday 5 — September 12, 2025

FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency